FUNI (Hypha Labs) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hypha Labs Change In Receivables?

Hypha Labs's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Hypha Labs's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Hypha Labs's change in receivables for the fiscal year that ended in Sep. 2024 was $0.00 Mil. It means Hypha Labs's Accounts Receivable stayed the same from Sep. 2023 to Sep. 2024 .

Hypha Labs's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hypha Labs's liquidation value for the three months ended in Dec. 2024 was $-1.45 Mil.

Hypha Labs Change In Receivables Historical Data

The historical data trend for Hypha Labs's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypha Labs Change In Receivables Chart

Hypha Labs Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Change In Receivables

Get a 7-Day Free Trial

-0.15

0.06

-0.19

Hypha Labs Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Hypha Labs Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Hypha Labs (OTCPK:FUNI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hypha Labs's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Hypha Labs's accounts receivable are only considered to be worth 75% of book value:

Hypha Labs's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.037	-	1.49	+	0.75 * 0	+	0.5 * 0
=	-1.45

Hypha Labs Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hypha Labs's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hypha Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hypha Labs Inc (OTCPK:FUNI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

5940 S. Rainbow Boulevard, Las Vegas, NV, USA, 89118

Website

https://www.hyphalabs.com

Hypha Labs Inc is engaged in the research, development and commercialization of a bioreactor, the Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of nutritionally beneficial mushrooms for human consumption.

Executives

A Stone Douglass	director	10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank	director	19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda	officer: Chief Executive Officer	111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann	director	1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben	director	430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser	director	4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer	director	287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco	director	611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson	officer: Chief Financial Officer	3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner	director	28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc	10 percent owner	16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin	director, officer: President	C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee	10 percent owner	3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen	director, 10 percent owner, officer: CFO	8908 SPLITARROW DRIVE, AUSTIN TX 78717